<DOC>
	<DOCNO>NCT00952848</DOCNO>
	<brief_summary>RATIONALE : Electronic stimulation use MC5-A Scrambler may help relieve pain patient develop peripheral neuropathy undergo chemotherapy treatment cancer . PURPOSE : This phase II trial study well MC5-A Scrambler therapy work reduce peripheral neuropathy cause chemotherapy .</brief_summary>
	<brief_title>Electrical Stimulation Therapy Using MC5-A Scrambler Reducing Peripheral Neuropathy Caused Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine MC5-A Scrambler therapy improve pain associate chemotherapy-induced peripheral neuropathy cancer patient 20 % . Secondary - To evaluate effect MC5-A therapy specific pain neuropathy scale . - To evaluate effect MC5-A therapy overall quality life . - To evaluate effect MC5-A therapy pain drug use . - To evaluate toxicity MC5-A therapy . OUTLINE : Patients undergo gel electrode application skin pain-free pain-affected area . Patients undergo treatment MC5-A Scrambler machine 60 minute daily day 1-10 . On day 1 , treatment intensity increase every 10 minute maximum intensity individually bearable patient without input pain discomfort . The patient feel disappearance pain treatment sign proper nerve pathway ( ) ( ) correctly identify . Subsequent treatment begin high intensity tolerate previous treatment . Patients improvement 3 treatment discontinue treatment . Patients complete questionnaire symptom , pain , quality life periodically . After completion study treatment , patient follow 2 4 week , monthly 3 month , 6 month .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chemotherapyinduced peripheral neuropathy ( CIPN ) meeting follow criterion : More 4 week since prior neurotoxic chemotherapy include taxanes ( e.g. , paclitaxel docetaxel ) , platinumbased compound ( e.g. , carboplatin , cisplatinum , oxaliplatin ) , vincaalkaloids ( e.g. , vincristine , vinblastine , vinorelbine ) , proteosome inhibitor ( e.g. , bortezomib ) Pain symptoms peripheral neuropathy ≥ 1 month attribute CIPN Pain stable ≥ 2 week Average daily pain rating ≥ 5 10 use pain numerical rating scale ( 0 pain 10 bad pain possible ) No symptomatic brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction intolerance transcutaneous electronic nerve stimulation No pacemaker implantable drugdelivery system ( e.g. , Medtronic Synchromed ) No heart stent vena cava clip No history epilepsy brain damage No identified cause painful paresthesias exist chemotherapy ( e.g. , radiation malignant plexopathy , lumbar cervical radiculopathy , preexist peripheral neuropathy another etiology [ e.g. , B12 deficiency , AIDS , monoclonal gammopathy , diabetes , heavy metal poison amyloidosis , syphilis , hyperthyroidism , hypothyroidism , inherit neuropathy , etc . ] ) No skin condition ( e.g. , open sore ) would prevent proper application electrodes No medical condition , opinion investigator , might compromise objective study PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 30 day since prior concurrent investigational agent pain control More 4 week since prior concurrent celiac plexus block neurolytic pain control treatment No prior concurrent anticonvulsant No concurrent neurotoxic potentially neurotoxic chemotherapy Concurrent pain treatment allow provide follow criterion meet : Pain satisfactorily control Dose medication stable ≥ 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>pain</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>peripheral neuropathy</keyword>
</DOC>